by EmpathiCSubstanceS | Dec 26, 2018 | Anxiety
Three new books suggest that psychedelic drugs did not necessarily have the power to rewrite society, but, instead, brought on revelations concerning earthly themes. In 1960, Allen Ginsberg wrote a letter to Timothy Leary, then a professor at Harvard. Leary had...
by EmpathiCSubstanceS | Dec 26, 2018 | Addiction
Psychedelic drugs like LSD and ecstasy ingredient MDMA have been shown to stimulate the growth of new branches and connections between brain cells which could help address conditions like depression and addiction. Researchers in California have demonstrated these...
by EmpathiCSubstanceS | Dec 26, 2018 | Depression
The subgranular zone (SGZ) of dentate gyrus (DG) is one of the few regions in which neurogenesis is maintained throughout adulthood. It is believed that newborn neurons in this region encode temporal information about partially overlapping contextual memories. The...
by EmpathiCSubstanceS | Dec 26, 2018 | Kambo
If phase III clinical trials are successful, researchers suggest categorizing the drug as schedule IV In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, researchers suggest that if it clears phase III clinical trials, psilocybin...
by EmpathiCSubstanceS | Dec 26, 2018 | Anxiety
Researchers at Johns Hopkins University have suggested that psilocybin, which is found in hallucinogenic mushrooms, be reclassified from a Schedule I drug, with no known medical benefit, to a Schedule IV drug, which is akin to prescription sleeping pills....
